The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.

[1]  Y. Yamada,et al.  Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. , 2013, Brachytherapy.

[2]  Liying Zhang,et al.  Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Liying Zhang,et al.  Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. , 2010, International journal of radiation oncology, biology, physics.

[4]  P. Unger,et al.  Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy. , 2009, Pathology, research and practice.

[5]  F. García-Vicente,et al.  Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? , 2009, European urology.

[6]  G. Lockwood,et al.  Twenty‐four‐month postradiation prostate biopsies are strongly predictive of 7‐year disease‐free survival , 2009, Cancer.

[7]  Luc Beaulieu,et al.  An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. , 2007, International journal of radiation oncology, biology, physics.

[8]  Victor E Reuter,et al.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. , 2008, The Journal of urology.

[9]  Peter Bownes,et al.  High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  P. Unger,et al.  Patterns of local failure following prostate brachytherapy. , 2007, The Journal of urology.

[11]  D. Kuban,et al.  The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. , 2007, International journal of radiation oncology, biology, physics.

[12]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[13]  R. Bristow,et al.  A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  D. Kuban,et al.  Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. , 2002, International journal of radiation oncology, biology, physics.

[15]  G. Gustafson,et al.  Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[16]  G Starkschall,et al.  Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Perry,et al.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. , 2000, International journal of radiation oncology, biology, physics.

[18]  P. Schellhammer,et al.  Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .